BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Device: BETACONNECT device

First Posted Date: 2016-01-11

Last Posted Date: 2018-09-06

Lead Sponsor: Bayer

Target Recruit Count: 146

Registration Number: NCT02652091

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion

Completed

Conditions: Retinal Vein Occlusion

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2016-01-05

Last Posted Date: 2018-09-06

Lead Sponsor: Bayer

Target Recruit Count: 126

Registration Number: NCT02645747

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Phase 1

Completed

Conditions: Medical Oncology

Interventions: Drug: BAY 94-9343
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2015-12-24

Last Posted Date: 2019-11-07

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT02639091

A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries

Completed

Conditions: Hypertension, Pulmonary

Interventions: Other: Standard of care

First Posted Date: 2015-12-22

Last Posted Date: 2021-08-25

Lead Sponsor: Bayer

Target Recruit Count: 231

Registration Number: NCT02637050

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Phase 1

Active, not recruiting

Conditions: Solid Tumors Harboring NTRK Fusion

Interventions: Drug: Larotrectinib (Vitrakvi, BAY2757556)

First Posted Date: 2015-12-22

Last Posted Date: 2024-12-24

Lead Sponsor: Bayer

Target Recruit Count: 154

Registration Number: NCT02637687

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Lucille Salter Packard Children's Hospital at Stanford, Palo Alto, California, United States

and more 42 locations

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Copanlisib (BAY80-6946)
Drug: Placebo
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Bendamustine
Drug: Prednisone

First Posted Date: 2015-12-10

Last Posted Date: 2024-12-11

Lead Sponsor: Bayer

Target Recruit Count: 551

Registration Number: NCT02626455

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center- Bergen, New York, New York, United States
🇧🇷
Hospital de Clinicas de Porto Alegre | Clinical Research Center - Surgery Research Center, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Irmandade da Santa Casa de Misericordia de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia, Porto Alegre, Rio Grande Do Sul, Brazil

and more 198 locations

A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi

Phase 3

Completed

Conditions: Chagas Disease

Interventions: Drug: Nifurtimox (Lampit, BAYA2502)
Drug: Placebo

First Posted Date: 2015-12-09

Last Posted Date: 2024-08-19

Lead Sponsor: Bayer

Target Recruit Count: 330

Registration Number: NCT02625974

Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Vericiguat (BAY1021189)
Drug: Placebo
Drug: Nitroglycerin

First Posted Date: 2015-12-01

Last Posted Date: 2021-12-29

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT02617550

To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea

Phase 3

Withdrawn

Conditions: Dysmenorrhea

Interventions: Drug: Placebo
Drug: EE20/DRSP(YAZ,BAY86-5300)

First Posted Date: 2015-12-01

Last Posted Date: 2016-02-17

Lead Sponsor: Bayer

Registration Number: NCT02617537

HCC Patient Preferences in Japan

Completed

Conditions: Hepatocellular Cancer

Interventions: Drug: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]

First Posted Date: 2015-11-30

Last Posted Date: 2017-09-27

Lead Sponsor: Bayer

Target Recruit Count: 120

Registration Number: NCT02616692

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy